{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:08:44Z","timestamp":1792152524150,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T00:00:00Z","timestamp":1429920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00223-015-0003-8","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T05:22:30Z","timestamp":1429852950000},"page":"477-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ibandronate Increases Sclerostin Levels and Bone Strength in Male Patients with Idiopathic Osteoporosis"],"prefix":"10.1007","volume":"96","author":[{"given":"Christian","family":"Muschitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kocijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Pahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina M.","family":"Patsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Misof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kaider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,25]]},"reference":[{"key":"3_CR1","volume-title":"Osteoporosis","author":"ES Orwoll","year":"2008","unstructured":"Orwoll ES, Klein RF (2008) Osteoporosis in men: epidemiology, pathophysiology, and clinical characterization. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis, vol 2, 3rd edn. Academic Press, New York","edition":"3"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/jbmr.344","volume":"26","author":"JM Patsch","year":"2011","unstructured":"Patsch JM, Kohler T, Berzlanovich A, Muschitz C, Bieglmayr C, Roschger P, Resch H, Pietschmann P (2011) Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res 26:1584\u20131592. doi: 10.1002\/jbmr.344","journal-title":"J Bone Miner Res"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00223-011-9466-4","volume":"88","author":"N Fratzl-Zelman","year":"2011","unstructured":"Fratzl-Zelman N, Roschger P, Misof BM, Nawrot-Wawrzyniak K, P\u00f6tter-Lang S, Muschitz C, Resch H, Klaushofer K, Zwettler E (2011) Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover. Calcif Tissue Int 88:378\u2013387. doi: 10.1007\/s00223-011-9466-4","journal-title":"Calcif Tissue Int"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S8756-3282(01)00478-1","volume":"29","author":"E Legrand","year":"2011","unstructured":"Legrand E, Hedde C, Gallois Y, Degasne I, Boux de Casson F, Mathieu E, Basl\u00e9 MF, Chappard D, Audran M (2011) Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone 29:90\u201395","journal-title":"Bone"},{"key":"3_CR5","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1210\/jc.2003-032081","volume":"89","author":"I Pottelbergh Van","year":"2004","unstructured":"Van Pottelbergh I, Goemaere S, Zmierczak H, Kaufman JM (2004) Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinol Metab 89:4949\u20134953. doi: 10.1210\/jc.2003-032081","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR6","first-page":"2795","volume":"82","author":"AG Johansson","year":"1997","unstructured":"Johansson AG, Eriksen EF, Lindh E, Langdahl B, Blum WF, Lindahl A, Ljunggren O, Ljunghall S (1997) Reduced serum levels of the growth hormone dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab 82:2795\u20132798. doi: 10.1210\/jcem.82.9.4148","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR7","first-page":"2799","volume":"82","author":"ES Kurland","year":"1997","unstructured":"Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP (1997) Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799\u20132805. doi: 10.1210\/jcem.82.9.4253","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2005.06.016","volume":"37","author":"MB Patel","year":"2005","unstructured":"Patel MB, Arden NK, Masterson LM, Phillips DI, Swaminathan R, Syddall HE, Byrne CD, Wood PJ, Cooper C, Holt RI et al (2005) Investigating the role of the growth hormone-insulin-like growth factor (GH-IGF) axis as a determinant of male bone mineral density (BMD). Bone 37:833\u2013841. doi: 10.1016\/j.bone.2005.06.016","journal-title":"Bone"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1210\/jc.2002-020231","volume":"87","author":"P Gillberg","year":"2002","unstructured":"Gillberg P, Mallmin H, Petr\u00e9n-Mallmin M, Ljunghall S, Nilsson AG (2002) Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 87:4900\u20134906. doi: 10.1210\/jc.2002-020231","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.exger.2014.05.014","volume":"57","author":"U F\u00f6ger-Samwald","year":"2014","unstructured":"F\u00f6ger-Samwald U, Patsch JM, Schamall D, Alaghebandan A, Deutschmann J, Salem S, Mousavi M, Pietschmann P (2014) Molecular evidence of osteoblast dysfunction in elderly men with osteoporotic hip fractures. Exp Gerontol 57:114\u2013121. doi: 10.1016\/j.exger.2014.05.014","journal-title":"Exp Gerontol"},{"key":"3_CR11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jbmr.2035","volume":"29","author":"BM Misof","year":"2014","unstructured":"Misof BM, Patsch JM, Roschger P, Muschitz C, Gamsjaeger S, Paschalis EP, Prokop E, Klaushofer K, Zwettler E (2014) Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res 29:440\u2013449. doi: 10.1002\/jbmr.2035","journal-title":"J Bone Miner Res"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-012-0003-1","volume":"73","author":"L Mosekilde","year":"2013","unstructured":"Mosekilde L, Vestergaard P, Rejnmark L (2013) The pathogenesis, treatment and prevention of osteoporosis in men. Drugs 73:15\u201329. doi: 10.1007\/s40265-012-0003-1","journal-title":"Drugs"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00198-012-1947-4","volume":"24","author":"RD Chapurlat","year":"2013","unstructured":"Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul MC (2013) Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int 24:311\u2013320. doi: 10.1007\/s00198-012-1947-4","journal-title":"Osteoporos Int"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2012-4039","volume":"98","author":"A Catalano","year":"2013","unstructured":"Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A (2013) Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 98:1911\u20131915. doi: 10.1210\/jc.2012-4039","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR15","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1210\/jc.2013-1402","volume":"98","author":"AD Anastasilakis","year":"2013","unstructured":"Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P (2013) Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 98:3206\u20133212. doi: 10.1210\/jc.2013-1402","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610. doi: 10.1056\/NEJM200008313430902","journal-title":"N Engl J Med"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1210\/jc.2012-4255","volume":"98","author":"BC Silva","year":"2013","unstructured":"Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J et al (2013) Trabecular bone score (TBS)\u2014a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98:1963\u20131970. doi: 10.1210\/jc.2012-4255","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530. doi: 10.1002\/jbmr.2176","journal-title":"J Bone Miner Res"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.jbiomech.2010.04.023","volume":"43","author":"E Dall\u2019Ara","year":"2010","unstructured":"Dall\u2019Ara E, Schmidt R, Pahr D, Varga P, Chevalier Y, Patsch J, Kainberger F, Zysset P (2010) A nonlinear finite element model validation study based on a novel experimental technique for inducing anterior wedge-shape fractures in human vertebral bodies in vitro. J Biomech 43:2374\u20132380. doi: 10.1016\/j.jbiomech.2010.04.023","journal-title":"J Biomech"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bone.2012.09.006","volume":"52","author":"E Dall\u2019Ara","year":"2013","unstructured":"Dall\u2019Ara E, Luisier B, Schmidt R, Kainberger F, Zysset P, Pahr D (2013) A nonlinear QCT-based finite element model validation study for the human femur tested in two configurations in vitro. Bone 52:27\u201338. doi: 10.1016\/j.bone.2012.09.006","journal-title":"Bone"},{"key":"3_CR21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","volume":"23","author":"YE Chung","year":"2012","unstructured":"Chung YE, Lee SH, Lee SY, Kim SY, Kim HH, Mirza FS, Lee SK, Lorenzo JA, Kim GS, Koh JM (2012) Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 23:1235\u20131243. doi: 10.1007\/s00198-011-1675-1","journal-title":"Osteoporos Int"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","volume":"23","author":"SA Polyzos","year":"2012","unstructured":"Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E (2012) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 23:1171\u20131176. doi: 10.1007\/s00198-010-1525-6","journal-title":"Osteoporos Int"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/jcb.24537","volume":"114","author":"K Ota","year":"2013","unstructured":"Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ (2013) Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem 114:1901\u20131907. doi: 10.1002\/jcb.24537","journal-title":"J Cell Biochem"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russel","year":"2008","unstructured":"Russel RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759. doi: 10.1007\/s00198-007-0540-8","journal-title":"Osteoporos Int"},{"key":"3_CR25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bone.2014.06.037","volume":"67","author":"D Gatti","year":"2014","unstructured":"Gatti D, Viapiana O, Idolazzi L, Fracassi E, Ionescu C, Dartizio C, Troplini S, Kunnathully V, Adami S, Rossini M (2014) Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. Bone 67:189\u2013192. doi: 10.1016\/j.bone.2014.06.037","journal-title":"Bone"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-013-9742-6","volume":"94","author":"JP Stains","year":"2014","unstructured":"Stains JP, Watkins MP, Grimston SK, Hebert C, Civitelli R (2014) Molecular mechanisms of osteoblast\/osteocyte regulation by connexin43. Calcif Tissue Int 94:55\u201367. doi: 10.1007\/s00223-013-9742-6","journal-title":"Calcif Tissue Int"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bone.2012.09.030","volume":"52","author":"LI Plotkin","year":"2013","unstructured":"Plotkin LI, Bellido T (2013) Beyond gap junctions: connexin43 and bone cell signaling. Bone 52:157\u2013166. doi: 10.1016\/j.bone.2012.09.030","journal-title":"Bone"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00223-012-9628-z","volume":"91","author":"N Bivi","year":"2012","unstructured":"Bivi N, Nelson MT, Faillace ME, Li J, Miller LM, Plotkin LI (2012) Deletion of Cx43 from osteocytes results in defective bone material properties but does not decrease extrinsic strength in cortical bone. Calcif Tissue Int 91:215\u2013224. doi: 10.1007\/s00223-012-9628-z","journal-title":"Calcif Tissue Int"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","volume":"49","author":"T Bellido","year":"2011","unstructured":"Bellido T, Plotkin LI (2011) Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 49:50\u201355. doi: 10.1016\/j.bone.2010.08.008","journal-title":"Bone"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-012-1216-7","volume":"68","author":"N Maruotti","year":"2012","unstructured":"Maruotti N, Corrado A, Neve A, Cantatore FP (2012) Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol 68:1013\u20131018. doi: 10.1007\/s00228-012-1216-7","journal-title":"Eur J Clin Pharmacol"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00198-014-2808-0","volume":"25","author":"R Sapir-Koren","year":"2014","unstructured":"Sapir-Koren R, Livshits G (2014) Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos Int 25:2685\u20132700. doi: 10.1007\/s00198-014-2808-0","journal-title":"Osteoporos Int"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/jbmr.472","volume":"26","author":"X Li","year":"2011","unstructured":"Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D et al (2011) Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26:2610\u20132621. doi: 10.1002\/jbmr.472","journal-title":"J Bone Miner Res"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jbmr.2216","volume":"29","author":"C Muschitz","year":"2014","unstructured":"Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H (2014) Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density\u2014the CONFORS Study. J Bone Miner Res 29:1777\u20131785. doi: 10.1002\/jbmr.2216","journal-title":"J Bone Miner Res"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00198-011-1732-9","volume":"23","author":"HK Genant","year":"2012","unstructured":"Genant HK, Lewiecki EM, Fuerst T, Fries M (2012) Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporos Int 23:257\u2013265. doi: 10.1007\/s00198-011-1732-9","journal-title":"Osteoporos Int"},{"key":"3_CR35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","volume":"46","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970\u2013976. doi: 10.1016\/j.bone.2009.12.034","journal-title":"Bone"},{"issue":"7","key":"3_CR36","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1359\/jbmr.090216","volume":"24","author":"A Fahrleitner-Pammer","year":"2009","unstructured":"Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24(7):1335\u20131344. doi: 10.1359\/jbmr.090216","journal-title":"J Bone Miner Res"},{"key":"3_CR37","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","volume":"86","author":"JD Ringe","year":"2001","unstructured":"Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252\u20135255. doi: 10.1210\/jcem.86.11.7988","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5\u00a0mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239\u20132250. doi: 10.1002\/jbmr.119","journal-title":"J Bone Miner Res"},{"key":"3_CR39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jbmr.2024","volume":"29","author":"TM Keaveny","year":"2014","unstructured":"Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP et al (2014) Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res 29:158\u2013165. doi: 10.1002\/jbmr.2024","journal-title":"J Bone Miner Res"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","volume":"97","author":"K Amrein","year":"2012","unstructured":"Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Fahrleitner-Pammer A (2012) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97:148\u2013154. doi: 10.1210\/jc.2011-2152","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR41","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1210\/jc.2013-2244","volume":"99","author":"R Kocijan","year":"2014","unstructured":"Kocijan R, Muschitz C, Fahrleitner-Pammer A, Amrein K, Pietschmann P, Haschka J, Dinu S, Kapiotis S, Resch H (2014) Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta. J Clin Endocrinol Metab 99:E311\u2013E319. doi: 10.1210\/jc.2013-2244","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3_CR42","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jbmr.1888","volume":"28","author":"P Szulc","year":"2013","unstructured":"Szulc P, Boutroy S, Vilayphiou N, Schoppet M, Rauner M, Chapurlat R, Hamann C, Hofbauer LC (2013) Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res 28(8):1760\u20131770. doi: 10.1002\/jbmr.1888","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-015-0003-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0003-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:41:12Z","timestamp":1558698072000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-015-0003-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,25]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s00223-015-0003-8","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,25]]}}}